Nemolizumab provides significant relief from itch and skin lesions in prurigo nodularis and atopic dermatitis, with sustained efficacy over two years. The biologic targets the interleukin-31 ...

The drug already holds approvals to treat prurigo nodularis, as well as atopic dermatitis, another chronic skin condition. Commenting on the latest results for the drug, Baldo Scassellati Sforzolini, ...

One of the key drivers of the global prurigo nodularis market is the rising incidence of the condition, particularly among patients with underlying skin disorders like atopic dermatitis and eczema.

Atopic dermatitis manifests differently on dark versus light skin, making equitable treatment challenging.

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest data drop in prurigo nodularis carries a mix of both positives and ...

The FDA has approved Nemluvio for treating moderate to severe atopic dermatitis, a type of eczema, in people aged 12 or older.

Prurigo nodularis is a serious skin condition characterized by several debilitating symptoms, including chronic itch, skin nodules covering large body areas, and poor sleep quality. 5-7,10 The ...

Dermatosis papulosa nigra (DPN) affects many people of colour especially as skin matures. Here's your guide to what it is and how/ if to treat it.

Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly ...

The Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab-ilto) for the treatment of adults with prurigo nodularis.

The approval stipulates use in adults with prurigo nodularis, a skin condition characterized by chronic itch, nodules covering large areas of the body, and poor sleep quality. Driven by IL-31 ...